David Wurzer - British Amer Independent Director
| BTI Stock | CAD 0.01 1.24 99.60% |
Director
Mr. David M. Wurzer is Independent Director of the Company. He is currently serves as executive vice president and chief investment officer at Connecticut Innovations in Rocky Hill, Conn. Mr. Wurzer is responsible for managing the investment function at CI, which includes staffing, portfolio and risk management, outreach, budget planning and performance measurement. He also is responsible for oversight of the Connecticut Bioscience Innovation Fund and the Regenerative Medicine Research Fund . When Mr. Wurzer joined CI in 2009 as senior managing director of investments, he had extensive seniorlevel experience in operations and finance, including more than 10 years as executive vice president, treasurer and chief financial officer of CuraGen Corporationrationration, a former CI portfolio company. Mr. Wurzer guided the biotech company through its initial public offering and helped raise more than 700 million. Mr. Wurzer was also involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies, including Roche, Bayer and AmgenFreemont . Mr. Wurzer helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as 5.3 billion. Mr. Wurzer began his professional career with Coopers Lybrand in Hartford, Conn., where he held various accounting and managerial positions. Mr. Wurzer currently serves on the board of directors for several private and public companies, including Standard Diversified Opportunities, Inc., Summit Therapeutics, ReNetX Therapeutics, Natural Polymer Devices, Thetis Pharmaceuticals. His various responsibilities on these boards include lead director, audit committee chair, compensation committee chair, nominating member and audit and compensation committee member. since 2018.
| Tenure | 6 years |
| Address | 157 Church Street, New Haven, CT, United States, 06510 |
| Phone | 203 533 7082 |
| Web | https://www.bioasis.us |
British Amer Management Efficiency
The company has return on total asset (ROA) of (0.8058) % which means that it has lost $0.8058 on every $100 spent on assets. This is way below average. British Amer's management efficiency ratios could be used to measure how well British Amer manages its routine affairs as well as how well it operates its assets and liabilities. At this time, British Amer's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.54 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.59). At this time, British Amer's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 452.7 K in 2024, whereas Total Current Assets are likely to drop slightly above 711.9 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Raymond Chun | Toronto Dominion Bank | N/A | |
| JeanRene Halde | Toronto Dominion Bank | 70 | |
| Karen Maidment | Toronto Dominion Bank | 60 | |
| Brian Ferguson | Toronto Dominion Bank | 62 | |
| Michael McCain | Royal Bank of | 60 | |
| Jeffery Yabuki | Royal Bank of | 59 | |
| Jacynthe Cote | Royal Bank of | 60 | |
| Andrew Chisholm | Royal Bank of | 59 | |
| Thierry Vandal | Royal Bank of | 58 | |
| Heather MunroeBlum | Royal Bank of | 68 | |
| Claude Mongeau | Toronto Dominion Bank | 57 | |
| Alan MacGibbon | Toronto Dominion Bank | 63 | |
| Irene Miller | Toronto Dominion Bank | 67 | |
| David Denison | Royal Bank of | 66 | |
| Nadir Mohamed | Toronto Dominion Bank | 63 | |
| Toos Daruvala | Royal Bank of | 63 | |
| Bridget Kralingen | Royal Bank of | 55 | |
| David Kepler | Toronto Dominion Bank | 66 | |
| Colleen Goggins | Toronto Dominion Bank | 64 | |
| Amy Brinkley | Toronto Dominion Bank | 63 | |
| Alice Laberge | Royal Bank of | 62 | |
Management Performance
| Return On Asset | -0.81 |
biOasis Technologies Leadership Team
Elected by the shareholders, the British Amer's board of directors comprises two types of representatives: British Amer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of British. The board's role is to monitor British Amer's management team and ensure that shareholders' interests are well served. British Amer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, British Amer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Wurzer, Independent Director | ||
| Doug Williams, Executive Vice-President Chief Business Officer | ||
| David Jenkins, Chief Officer | ||
| Mario Saltarelli, Non-Executive Director | ||
| Graeme Dick, Director Relations | ||
| Doug MBA, Exec Officer | ||
| Christine Antalik, Chief Financial Officer | ||
| John Curran, Independent Director | ||
| Kim Elton, Director Marketing | ||
| Caroline Dircks, Chief Operating Officer | ||
| Deborah Rathjen, Executive Chairman of the Board, President, Chief Executive Officer | ||
| Aaron Elton, Director Marketing | ||
| Mei Tian, VP Research | ||
| Dave Jenkins, Chief Officer | ||
| B FTSE, CEO Chairman |
British Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is British Amer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.81 | ||||
| Operating Margin | (4.69) % | ||||
| Current Valuation | 2.45 M | ||||
| Shares Outstanding | 79.41 M | ||||
| Shares Owned By Insiders | 2.05 % | ||||
| Number Of Shares Shorted | 105.04 K | ||||
| Price To Earning | 25.91 X | ||||
| Price To Book | 54.04 X | ||||
| Price To Sales | 1.47 X | ||||
| Revenue | 269.38 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for British Stock Analysis
When running British Amer's price analysis, check to measure British Amer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy British Amer is operating at the current time. Most of British Amer's value examination focuses on studying past and present price action to predict the probability of British Amer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move British Amer's price. Additionally, you may evaluate how the addition of British Amer to your portfolios can decrease your overall portfolio volatility.